Catalyst
Slingshot members are tracking this event:
Shire (SHPG) Phase 1b Results Evaluating Lanadelumab in Treatment of Hereditary Angioedema (HAE) Published in the New England Journal of Medicine
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SHPG |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 23, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1b, Lanadelumab, Hereditary Angioedema, New England Journal Of Medicine
